Why the study?
Does P2Y12 inhibitor intensity de-escalation impact bleeding and ischaemic risk in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Does P2Y12 inhibitor intensity de-escalation impact bleeding and ischaemic risk in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
The paper discusses the dynamics of bleeding and ischemic risk and the potential impact of de-escalating antiplatelet therapy in ACS patients undergoing PCI.
Dynamics of bleeding and ischaemic risk in patients with acute coronary syndrome undergoing percutaneous coronary intervention and potential impact of antiplatelet therapy de-escalation.
No takes yet. Share an insight, caveat, or question.
Ndrepepa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: